Few types of cancer have had their treatment evolve as rapidly as metastatic renal cell carcinoma (mRCC).
Since 2005, six new targeted therapies with proven efficacy have been approved for the treatment of mRCC. The downside is that our knowledge about the mechanisms of action of these therapies and the intrinsic and extrinsic mechanism of resistance has not evolved equally fast, and many questions remain unanswered. The only approved agent to date in the European Union for patients who progress on sunitinib or sorafenib is everolimus. The results of the phase III trial comparing axitinib vs. sorafenib after failure on sunitinib, bevacizumab, temsirolimus, or cytokines have recently been published, and axitinib has recently been licensed by the Food and Drugs Administration. Other phase III trials that are being conducted include a comparison between everolimus plus bevacizumab and everolimus after failure on tyrosine kinase inhibitors, and between temsirolimus and sorafenib after failure on sunitinib. In this article, we will review the available evidence from clinical studies on sequential therapy for mRCC, including those that are still in progress. In addition, information on the mechanism of resistance or tolerance to first-line therapy, recommendations of the main practice guidelines for second-line treatment, potential therapies for third or successive treatment lines, and the major reasons why patients who progress may benefit from a change of mechanism of action will also be discussed.
Written by:
Larriba JL, Espinosa E, Carbonero IG, García-Donas J, López M, Meana A, Puente J, Bellmunt J. Are you the author?
Hospital Clínico San Carlos, Madrid, Spain.
Reference: Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:11-7.
doi: 10.1007/s10555-012-9354-z
PubMed Abstract
PMID: 22674353
UroToday.com Renal Cancer Section
